Curaleaf (OTCMKTS:CURLF – Get Free Report) was downgraded by Cormark from a “moderate buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.
Separately, Needham & Company LLC reissued a “buy” rating and set a $6.25 price objective on shares of Curaleaf in a report on Thursday, August 8th.
Get Our Latest Analysis on Curaleaf
Curaleaf Stock Up 3.6 %
Curaleaf (OTCMKTS:CURLF – Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $342.29 million for the quarter, compared to the consensus estimate of $344.57 million. Curaleaf had a negative net margin of 18.59% and a negative return on equity of 14.75%. As a group, equities research analysts expect that Curaleaf will post -0.24 earnings per share for the current fiscal year.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Featured Stories
- Five stocks we like better than Curaleaf
- How to Use the MarketBeat Dividend Calculator
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- What is Put Option Volume?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Best Aerospace Stocks Investing
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.